February 27, 2015 7:48 PM ET


Company Overview of LiRIS Biomedical, Inc.

Company Overview

LiRIS Biomedical, Inc. operates as a pharmaceutical company. The company develops a portfolio of therapeutics to provide controlled-release of drugs directly to target tissues (bladders) to treat bladder diseases. It also offers LiRIS for the treatment of interstitial cystitis. The company was founded in 2008 and is based in Lexington, Massachusetts.

99 Hayden Avenue

Suite 100

Lexington, MA 02421

United States

Founded in 2008





Key Executives for LiRIS Biomedical, Inc.

Chief Executive Officer, President and Director
Co-Founder, Scientific Advisor and Director
Age: 54
Chief Financial Officer
Chief Business Officer and Senior Vice President
Chief Technology Officer
Compensation as of Fiscal Year 2014.

LiRIS Biomedical, Inc. Key Developments

TARIS BioMedical Enters Research Collaboration with AstraZeneca for Improved Bladder Cancer Treatments

TARIS Biomedical announced that it has entered into a research collaboration with AstraZeneca to evaluate novel treatments for bladder cancer. Under the terms of the agreement, the companies will work together to evaluate multiple novel cancer therapeutics by employing the TARIS(R) proprietary bladder delivery platform in combination with targeted cancer therapeutics from AstraZeneca. The TARIS(R) delivery platform is a soft, flexible system deployed into and retrieved from the bladder using standard urological office procedures. It is designed to provide continuous local delivery to the bladder for days to weeks, depending on the therapeutic application. Furthermore, AstraZeneca has an exclusive option to take a license to the products resulting from the collaboration. This could combine the ability to target both the right tissue - the tumour, with the right genetically targeted therapy and therefore represent a step change in the treatment of this disease.

TARIS BioMedical, Inc. Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate

TARIS BioMedical, Inc. announced that it has raised an additional $12.5 million financing round through its existing investors, Flagship Ventures, Flybridge Capital Partners, Polaris Partners and Third Rock Ventures. Including this round, TARIS(R) has raised a total of $49.8 million. The company also announced dosing of its first patient in its second randomized, placebo controlled Phase 2 study of LiRIS(R) in Interstitial Cystitis. This study is being conducted in the US and Canada, and is currently open for enrollment. In addition to Interstitial Cystitis, TARIS(R) is developing a pipeline of novel, targeted therapies designed to treat a variety of bladder diseases, such as bladder cancer and urinary incontinence, utilizing its novel targeted bladder delivery system.

Similar Private Companies By Industry

Company Name Region
Pasteuria Bioscience, Inc. United States
TARA Biosystems, Inc. United States
Hairbiotech Inc United States
Avid Radiopharmaceuticals, Inc. United States
Akeso Biomedical, Inc. United States

Recent Private Companies Transactions

August 13, 2014
TARIS BioMedical, Inc., LiRIS Program in Phase 2

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LiRIS Biomedical, Inc., please visit www.tarisbiomedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.